ClinicalTrials.gg
RecruitingNCT07588854EUS-SWQ-202601Updated May 15, 2026

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease

An observational study in Chronic Liver Disease (CLD) and Liver Fibrosis, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Liver Cirrhosis with a site in China — 66 open to participants now, 74 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
83rd of 88
65 · median 461
Started
2026
with 20 others
Observational
88 of 216
26 open now
Primary completion
2028-01
later than 50 of 73 live
Registered
197th of 216
by date

Among the 216 studies in Liver Cirrhosis with a site in China, this one is the 83rd largest by planned enrollment of the 88 observational ones that give a count, is one of 21 that started in 2026, is one of 88 observational ones, reaches primary completion later than 50 of the 73 other live ones, and was the 197th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

66 of the 216 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ.

The main questions it aims to answer are:

How closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value.

Participants will:

Be adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.

03

Conditions studied

  • Chronic Liver Disease (CLD)
  • Liver Fibrosis

Browse trials for

Keywords

  • Chronic liver disease
  • Liver fibrosis
  • EUS-SWQ
  • Endoscopic ultrasound
  • Liver biopsy
  • FibroScan
  • Olympus EU-ME3
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a single cohort observational study enrolling adult patients aged 18 to 80 years with chronic liver disease who meet clinical indications for EUS-guided liver biopsy. Candidates will undergo EUS-SWQ and FibroScan examinations before biopsy for the evaluation of liver fibrosis. Patients with contraindications to endoscopy, coagulopathy, severe comorbidities, decompensated cirrhosis, or suspected liver malignancy are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 80 years.
  2. Patients with clinical indications scheduled to undergo liver (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:;Fatty liver disease; hepatitis;Other chronic liver diseases of unknown etiology that would benefit from liver biopsy
  3. Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.
  4. Willing to provide and sign written .

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to tolerate endoscopic procedures.
  2. Patients with to endoscopy or anesthesia.
  3. Coagulopathy ( count \< 50×10⁹/L, PT > by 3 seconds).
  4. Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.
  5. Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.
  6. Patients with imaging findings suggestive of malignant liver tumors.
  7. Pregnant or lactating women.
  8. Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).
  9. Patients who refuse to participate in the clinical study.
  10. Any other conditions deemed inappropriate by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes

Groups and cohorts

  • One cohort of 65 adult patients with chronic liver disease who are scheduled to undergo clinically i

    Sixty-five patients with chronic liver disease who are scheduled to undergo clinically indicated liver biopsy. Only clinically indicated examinations including EUS-SWQ, FibroScan, and liver biopsy will be performed. No experimental drug or device intervention is administered in this study.

06

What researchers measure

Primary outcomes

  1. Correlation between EUS-SWQ measurements and METAVIR liver fibrosis staging

    To assess the correlation between EUS-SWQ measurements and liver fibrosis pathology stages (METAVIR F0-F4) using liver biopsy as the reference standard.

    Time frame: 2 weeks after the intervention

Secondary outcomes

  1. Comparison of correlation with liver fibrosis between EUS-SWQ and FibroScan

    To compare the correlation of EUS-SWQ and FibroScan measurements with histologically confirmed liver fibrosis stages.

    Time frame: At baseline

  2. Safety and measurement success rate of EUS-SWQ

    To evaluate the safety and technical success rate of EUS-SWQ measurement in patients with chronic liver disease.

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jan 2028, 20 months later.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 20 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 15, 2026
StartEst.
May 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07588854
Responsible party
Baiwen Li (Principal Investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
May 15, 2026
Start date
May 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 15, 2026

Study contacts

Baiwen Li, MD
Contact
muzibowen@126.com
86-21-37798480
Baiwen Li, MD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion